Germany: Affimed prices upsized offering of common shares

Nasdaq-listed Affimed, a clinical-stage immuno-oncology company, has priced a public offering of 22.5 million of its common shares at US$4.00 per share to raise US$90m – upsized from an initial plan to raise US$75m. There is also a 15% overallotment option. Proceeds for the share sale will help fund expanded trials of two cancer drugs….

You must be a HMI Subscriber to view this content.

Subscribe Now »